In particular, a case report on the use of vemurafenib in a MM patient with BRAF V600E mutation and the absence of RAS aberrations showed durable response with no signs of progressive disease or secondary malignancies after eight months [143]. The gene discussed is BRAF; the disease is Miyoshi myopathy.